R&D News | pharmaphorum

News

Prof Jean-Phillipe Vert, Owkin's chief R&D officer

Bioptimus born with $35m for a foundation model for biology

A team of scientists formerly working at Google DeepMind and Owkin have joined forces to create Bioptimus, a start-up that will apply generative artificial intelligence (G

News

Bayer takes novel deep vein thrombosis drug into phase 2

Bayer has started proof-of-concept testing of a potential new therapy for patients with deep vein thrombosis (DVT) that works in a different way to current drugs.

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

News

Gilead’s CD47 woes continue, this time in solid tumours

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug

News

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac

News

Freenome raises $254m for cancer tests, and other financings

Our round-up of recent biotech financings is headed by a $254 million private financing for cancer blood test specialist Freenome, with sizeable rounds for Cogent Bioscien

Bioptimus born with $35m for a foundation model for biology

Bayer takes novel deep vein thrombosis drug into phase 2

AZ, Daiichi eye December verdict for TROP2 ADC

Gilead’s CD47 woes continue, this time in solid tumours

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Freenome raises $254m for cancer tests, and other financings

German sites added to Europe's cardiometabolic R&D network

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks